Document is current
Any future updates will be listed below
-
Authors
Kalinovsky, Daniel V https://orcid.org/0000-0001-8773-2797
Kibardin, Alexey V
Kholodenko, Irina V
Svirshchevskaya, Elena V
Doronin, Igor I
Konovalova, Mariya V https://orcid.org/0000-0003-3923-6304
Grechikhina, Maria V
Rozov, Fedor N
Larin, Sergey S
Deyev, Sergey M
Kholodenko, Roman V https://orcid.org/0000-0001-6083-6588
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02452554 at ClinicalTrials.govnct03425279 at ClinicalTrials.govDocuments that mention this clinical trial
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
nct02988817 at ClinicalTrials.govDocuments that mention this clinical trial
Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e15010
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
nct03729596 at ClinicalTrials.govDocuments that mention this clinical trial
The clinical landscape of antibody-drug conjugates in endometrial cancer
https://doi.org/10.1136/ijgc-2024-005607
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
nct03504488 at ClinicalTrials.govDocuments that mention this clinical trial
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells
https://doi.org/10.1136/jitc-2022-004875
757 A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST)
https://doi.org/10.1136/jitc-2022-sitc2022.0757
nct02221505 at ClinicalTrials.govDocuments that mention this clinical trial
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
Documents that mention this clinical trial
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
https://doi.org/10.1136/jitc-2022-004646
-
Funding
Funding for this research was provided by:
Russian Science Foundation (21-74-30016)
- License Information
